Toll Free: 1-888-928-9744

Progen Pharmaceuticals Limited - Product Pipeline Review - 2015

Published: Dec, 2015 | Pages: 31 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Progen Pharmaceuticals Limited - Product Pipeline Review - 2015

Summary

Global Markets Direct's, 'Progen Pharmaceuticals Limited - Product Pipeline Review - 2015', provides an overview of the Progen Pharmaceuticals Limited's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Progen Pharmaceuticals Limited's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides brief overview of Progen Pharmaceuticals Limited including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Progen Pharmaceuticals Limited's human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones 
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement 
- Latest news and deals relating to the Progen Pharmaceuticals Limited's pipeline products

Reasons to Buy

- Evaluate Progen Pharmaceuticals Limited's strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Progen Pharmaceuticals Limited in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Progen Pharmaceuticals Limited's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Progen Pharmaceuticals Limited and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Progen Pharmaceuticals Limited
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Progen Pharmaceuticals Limited and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
 Table of Contents
Table of Contents 2 List of Tables 3 List of Figures 3 Progen Pharmaceuticals Limited Snapshot 4 Progen Pharmaceuticals Limited Overview 4 Key Information 4 Key Facts 4 Progen Pharmaceuticals Limited - Research and Development Overview 5 Key Therapeutic Areas 5 Progen Pharmaceuticals Limited - Pipeline Review 7 Pipeline Products by Stage of Development 7 Pipeline Products - Monotherapy 8 Progen Pharmaceuticals Limited - Pipeline Products Glance 9 Progen Pharmaceuticals Limited - Late Stage Pipeline Products 9 Phase III Products/Combination Treatment Modalities 9 Progen Pharmaceuticals Limited - Clinical Stage Pipeline Products 10 Phase I Products/Combination Treatment Modalities 10 Progen Pharmaceuticals Limited - Early Stage Pipeline Products 11 Preclinical Products/Combination Treatment Modalities 11 Discovery Products/Combination Treatment Modalities 12 Progen Pharmaceuticals Limited - Drug Profiles 13 muparfostat sodium 13 Product Description 13 Mechanism of Action 13 R&D Progress 13 PG-545 16 Product Description 16 Mechanism of Action 16 R&D Progress 16 Small Molecules to Target Heparanase for Oncology, Immunology and Diabetes 18 Product Description 18 Mechanism of Action 18 R&D Progress 18 Progen Pharmaceuticals Limited - Pipeline Analysis 19 Progen Pharmaceuticals Limited - Pipeline Products by Target 19 Progen Pharmaceuticals Limited - Pipeline Products by Route of Administration 20 Progen Pharmaceuticals Limited - Pipeline Products by Molecule Type 21 Progen Pharmaceuticals Limited - Pipeline Products by Mechanism of Action 22 Progen Pharmaceuticals Limited - Recent Pipeline Updates 23 Progen Pharmaceuticals Limited - Dormant Projects 25 Progen Pharmaceuticals Limited - Discontinued Pipeline Products 26 Discontinued Pipeline Product Profiles 26 PG-562 26 Progen Pharmaceuticals Limited - Company Statement 27 Progen Pharmaceuticals Limited - Locations And Subsidiaries 29 Head Office 29 Other Locations & Subsidiaries 29 Appendix 30 Methodology 30 Coverage 30 Secondary Research 30 Primary Research 30 Expert Panel Validation 30 Contact Us 30 Disclaimer 31
List of Tables
Progen Pharmaceuticals Limited, Key Information 4 Progen Pharmaceuticals Limited, Key Facts 4 Progen Pharmaceuticals Limited - Pipeline by Indication, 2015 6 Progen Pharmaceuticals Limited - Pipeline by Stage of Development, 2015 7 Progen Pharmaceuticals Limited - Monotherapy Products in Pipeline, 2015 8 Progen Pharmaceuticals Limited - Phase III, 2015 9 Progen Pharmaceuticals Limited - Phase I, 2015 10 Progen Pharmaceuticals Limited - Preclinical, 2015 11 Progen Pharmaceuticals Limited - Discovery, 2015 12 Progen Pharmaceuticals Limited - Pipeline by Target, 2015 19 Progen Pharmaceuticals Limited - Pipeline by Route of Administration, 2015 20 Progen Pharmaceuticals Limited - Pipeline by Molecule Type, 2015 21 Progen Pharmaceuticals Limited - Pipeline Products by Mechanism of Action, 2015 22 Progen Pharmaceuticals Limited - Recent Pipeline Updates, 2015 23 Progen Pharmaceuticals Limited - Dormant Developmental Projects,2015 25 Progen Pharmaceuticals Limited - Discontinued Pipeline Products, 2015 26 Progen Pharmaceuticals Limited, Subsidiaries 29



                                

To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $1500
Multi User - US $3000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify